Search Ontology:
ChEBI
N-(3-{[alpha-D-GalN-(1->4)-alpha-D-GalN-(1->4)-alpha-D-GalN-yl]oxy}propyl)-21-(biotinylamino)-4,7,10,13,16,19-hexaoxadodecan-1-amide
- Term ID
- CHEBI:146263
- Synonyms
-
- (3aS,4S,6aR)-N-[25-[[O-2-amino-2-deoxy-alpha-D-galactopyranosyl-(1->4)-O-2-amino-2-deoxy-alpha-D-galactopyranosyl-(1->4)-2-amino-2-deoxy-alpha-D-galactopyranosyl]oxy]-21-oxo-3,6,9,12,15,18-hexaoxa-22-azapentacos-1-yl]hexahydro-2-oxo-1H-thieno[3,4-d]imidaz
- 3-(21-biotinamino-4,7,10,13,16,19-hexaoxagenicaminoamino)-propyl 2-amino-2-deoxy-alpha-D-galactopyranosyl-(1->4)-2-amino-2-deoxy-alpha-D-galactopyranosyl-(1->4)-2-amino-2-deoxy-alpha-D-galactopyranoside
- N-(3-{[2-amino-2-deoxy-alpha-D-galactopyranosyl-(1->4)-2-amino-2-deoxy-alpha-D-galactopyranosyl-(1->4)-2-amino-2-deoxy-alpha-D-galactopyranosyl]oxy}propyl)-23-oxo-27-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]-4,7,10,13,16,19-hexaoxa-22-az
- N-(3-{[alpha-D-galactosaminyl-(1->4)-alpha-D-galactosaminyl-(1->4)-alpha-D-galactosaminyl]oxy}propyl)-21-(biotinylamino)-4,7,10,13,16,19-hexaoxaheptacosan-1-amide
- Definition
- A trisaccharide derivative in which alpha-D-galactosaminyl-(1->4)-alpha-D-galactosaminyl-(1->4)-alpha-D-galactosamine is linked glycosidically to biotin via a (21-oxo-3,6,9,12,15,18-hexaoxa-22-azapentacosan-1-yl)amino spacer. One of a set of synthesised biotinylated oligo-alpha-(1->4)-D-galactosamines comprising from two to six monosaccharide units, along with their N-acetylated derivatives (PMID:31913631), aimed at analysing the specificity of the antibody responses to a complex exopolysaccharide galactosaminogalactan found in Aspergillus fumigatus, the most important airborne human fungal pathogen in industrialized countries.
- References
- Ontology
- ChEBI ( EBI )
- is a type of
-
Phenotype
Phenotype resulting from N-(3-{[alpha-D-GalN-(1->4)-alpha-D-GalN-(1->4)-alpha-D-GalN-yl]oxy}propyl)-21-(biotinylamino)-4,7,10,13,16,19-hexaoxadodecan-1-amide
Phenotype where environments contain N-(3-{[alpha-D-GalN-(1->4)-alpha-D-GalN-(1->4)-alpha-D-GalN-yl]oxy}propyl)-21-(biotinylamino)-4,7,10,13,16,19-hexaoxadodecan-1-amide
Phenotype modified by environments containing N-(3-{[alpha-D-GalN-(1->4)-alpha-D-GalN-(1->4)-alpha-D-GalN-yl]oxy}propyl)-21-(biotinylamino)-4,7,10,13,16,19-hexaoxadodecan-1-amide
Human Disease Model